Biotech Startups

CrossBridge Bio, launched in 2023, develops next-generation antibody-drug conjugates (ADCs) to address a range of cancer indications. The company originated from ADC technology developed at the University of Texas Health Science Center at Houston.

2 investors

Cryosa develops an incisionless medical treatment that uses controlled cooling to reduce tissue and open airways. The company serves patients requiring airway management procedures.

2 investors

CryoVeritas makes user-activated temperature indicators that integrate both time and temperature to confirm the integrity of vaccines and biospecimens exposed to heat during cold-chain storage down to −200 °C. Its "Pinktail" indicators are tunable from 5 minutes to 48+ hours and serve biorepositories, IVF/reproductive tissue banks, cell therapy, mRNA vaccine, blood banking, and forensic storage applications.

2 investors

CSafe develops temperature-controlled shipping solutions for the pharmaceutical and life sciences cold chain, including active and passive air cargo containers, parcel shippers, and cryogenic dewars for cell and gene therapies. It serves biopharma logistics worldwide with a network of service centers, manufacturing facilities, and real-time tracking technology.

2 investors

CTI is a venture investment firm and company builder that creates and scales biotech companies from early-stage ideas and assets, taking a therapeutic- and modality-agnostic approach. It focuses on advancing portfolio companies toward clinical development, regulatory approval, and exits through strategic acquisition.

2 investors

cTRL is a biotech company developing cell-based immunotherapies for cancer, drawing on expertise in the adaptive immune system, immuno-oncology, biomedical engineering, and cell therapy research and development.

2 investors

CU Anschutz is an academic medical campus focused on health professions education, biomedical research, and patient care across areas such as cancer, heart disease, Alzheimer's, and COVID-19. It trains future health professionals and conducts sponsored and philanthropically funded research.

2 investors

Cube Biotech develops the NativeMP™ platform, including Cubipol/SMALP copolymers and active full-length membrane protein targets, for isolating, purifying, and studying membrane proteins such as ion channels. It also offers custom protein services and bead functionalization used by research institutions for applications like antibody generation and Cryo-EM structural analysis.

2 investors

Cullgen is a privately held biopharmaceutical company developing first-in-class drugs based on its uSMITE™ (small-molecule induced ubiquitin-dependent target elimination) targeted protein degradation platform, which uses the ubiquitin-proteasome system and E3 ubiquitin ligases to target disease-causing proteins that conventional small-molecule drugs cannot reach. The company focuses on oncology and immune-related diseases and operates R&D and offices in both China and the United States.

2 investors

Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation. The company focuses on first- or best-in-class treatments to improve outcomes for patients managing these conditions.

2 investors

NeuLogiq is a research platform for clinical trials that integrates tablet-based cognitive assessments, EEG monitoring, and real-world behavioral data to measure brain function changes. The platform serves biopharma sponsors and clinical research sites conducting central nervous system studies across phases 0-3.

2 investors

Curavit designs and executes decentralized clinical trials using technology to improve patient outcomes and trial efficiency for pharmaceutical and medical device companies.

2 investors

Cure Genetics develops two biotechnology platforms: AIMS CAR-NKT, a cell therapy targeting solid tumors such as clear cell renal carcinoma, and the VELP directed-evolution library platform for gene therapy applications addressing the nervous system, heart, and kidneys. Its VELP platform has licensing collaborations with pharmaceutical companies including Boehringer Ingelheim.

2 investors

Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets. Its pipeline focuses on cancer, immunology, and inflammation.

2 investors

CurveBeam AI develops point-of-care cone beam CT imaging systems combined with AI and deep learning tools for orthopedic and bone health applications, including fragility fracture prevention. The company serves orthopedic and podiatric healthcare providers seeking diagnostic imaging and complementary software solutions.

2 investors

Acquired by Horizon Therapeutics in 2020.

2 investors

Cybele Microbiome studies how skincare ingredients affect the skin microbiome and its postbiotic output, using that knowledge in clinical trials to develop products with better efficacy and fewer side effects. It focuses on the link between ingredients, the microbiome, and human skin health.

2 investors

Cybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.

2 investors

Cyclana Bio is a biotech company developing therapeutic programs focused on the extracellular matrix and tissue-level disease biology, with a flagship focus on women's health conditions such as endometriosis. Based at the Babraham Research Campus in Cambridge, UK, its work builds on academic research into how the non-cellular component of tissue drives health and disease.

2 investors

CyGenica develops a targeted intracellular drug delivery technology, the GEENIE platform, to deliver therapeutic molecules into cells more safely and efficiently. Its work focuses on treatments for oncology and rare genetic diseases, serving biopharmaceutical companies developing therapies.

2 investors

Cyllene Therapeutics is a biotechnology company developing "pinpoint gene therapy" using a non-replicative HSV-1 based vector platform to deliver disease-modifying transgenes for peripheral nervous system disorders. Its lead asset, EG110A, is in clinical development for neurogenic detrusor overactivity (neurogenic bladder dysfunction).

2 investors

Cytel provides software and biometrics solutions for clinical trial design and delivery in the life sciences industry. The company serves pharmaceutical companies sponsoring clinical trials and their biometrics and biostatistics teams.

2 investors

Cytochroma provides genetically diverse iPSC-derived human cell models, high-throughput screening, and phenotypic data (branded "Wet AI") for drug discovery and preclinical validation. It serves pharmaceutical and biotech teams seeking donor-matched, multi-lineage cell panels across diverse populations to support safety, efficacy, and regulatory testing.

2 investors

Biopharmaceutical company using molecular biology to produce recombinant derivatives of botulinum neurotoxin for customized applications.

2 investors